381. [Supportive management of cisplatin and gemcitabine combination therapy for advanced biliary tract cancer].382. [Incidence and management of adverse events in FOLFOX plus bevacizumab therapy for colorectal cancer].383. [S-1 plus cisplatin(SP) for advanced gastric cancer].384. [Strategies to minimize toxicities during chemoradiotherapy for esophageal cancer].385. [Concurrent chemoradiotherapy with cisplatin for locally advanced squamous cell carcinoma of head and neck].386. [Management of side effects with platinum doublet chemotherapy used for treatment of non-small cell lung cancer].388. [Secondary malignant neoplasms].389. [Safety management of infusion reactions].390. [Allergic reaction and anaphylaxis].391. [Chemotherapy related gonadotoxicity].
作者: Keiko Kamoshita.;Kouhei Sugimoto.;Aiko Okamoto.;Nao Suzuki.
来源: Nihon Rinsho. 2015年73 Suppl 2卷507-13页 393. [Rhabdomyolysis].394. [Drug-induced arthralgias and myalgias].395. [Corneal epithelial disorder, lacrimal drainage obstruction, and conjunctivitis].397. [Ototoxicity of cisplatin].398. [Central nervous system neurotoxicity of anticancer chemotherapy].399. [Peripheral neuropathy].400. [Skin damage by extravasation of chemotherapeutic agents]. |